A Study of LY3025876 in Healthy Volunteers

Phase 1

Completed

Brief Summary: This trial is conducted in Singapore. The aim of this trial is to evaluate the safety and tolerability of the study drug in healthy people and investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.

Recruitment & Eligibility

Inclusion Criteria

Must be either a healthy male or a healthy female who cannot become pregnant
Have a body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m^2), inclusive, at screening

Exclusion Criteria

Are allergic to LY3025876 or related compounds
Have a history of significant disease that may affect the actions of drugs or may pose a risk when taking the study medication
Have a history of developing allergies, asthma, severe drug allergies (symptoms including, but not limited to, itching, red rashes, sores on the skin, scaling and shedding of skin), allergies or reactions to more than one drug, or have had bad reactions to skin creams containing corticosteroids. Corticosteroids are mainly used to control inflammation.

Arm && Interventions

Group	Intervention	Description
LY3025876	LY3025876	Single escalating doses of LY3025876 given as subcutaneous injections
Placebo	Placebo	0.9% sodium chloride given as a single subcutaneous injection

Primary Outcome Measures

Name	Time	Method
Number of Participants With 1 or More Drug-related Adverse Events or Any Serious Adverse Events	Baseline up to 28 days post-dose	Possible drug-relatedness of an adverse event (AE) was in the opinion of the investigator. A summary of all serious and all other non-serious AEs, regardless of any possible causality, is located in the Reported Adverse Event Module.

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics: Maximum Concentration (Cmax) of LY3025876	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose
Number of Participants Developing Anti-LY3025876 Antibodies	Day 28 post-dose	Blood samples were collected from all randomized participants to test for the development of antibodies binding to LY3025876.
Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3025876	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose	Area under the concentration-versus-time curve from time zero to infinity \[AUC(0-∞)\] of LY3025876.

Locations (1): For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇸🇬
Singapore, Singapore